Phase 1b, Open Label Study To Characterize The Distribution Of A Single Intravenous Dose Of [124i]-Iodobenzoyl (ib) Pf 06687234 With Concurrent Administration Of Non-radiolabeled Pf 06687234 As Assessed With Positron Emission Tomography And Computed Tomography (Pet-ct) Imaging In Moderate To Severe Ulcerative Colitis Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs F8 IL10 (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Oct 2018 Status changed from recruiting to suspended due to an interruption in supply of the radiolabeled material.
- 17 Sep 2018 Planned End Date changed from 26 Oct 2019 to 10 Dec 2019.
- 17 Sep 2018 Planned primary completion date changed from 26 Oct 2019 to 10 Dec 2019.